Is there a “gold” standard treatment for patients with isolated myeloid sarcoma?

Antić, Darko; Elezović, Ivo; Milić, Nataša; Suvajdžić, Nada; Vidović, Ana; Peruničić, Maja; Đjunić, Irena; Mitrović, Mirjana; Tomin, Dragica

doi:10.1016/j.biopha.2012.10.014

Cited by 78 publications

(84 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Systemic chemotherapy for isolated myeloid sarcoma had 65% of complete remission and 20 months of median survival regardless of radiotherapy [8]. Patients who underwent chemotherapy had a significantly longer overall survival and event-free survival time compared to those who did not undergo chemotherapy [10,11].…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, if neurologic symptom is accompanied, then surgical decompression should be considered first and then if myeloid sarcoma is diagnosed, systemic chemotherapy should be followed. The median time of progression to acute myeloid leukemia in patients with isolated myeloid sarcoma ranges from 5 to 12 months [3,6,9,10].…”

Section: Discussionmentioning

confidence: 99%

“…Patients with isolated myeloid sarcoma require close follow-up, since delayed or inadequately treated isolated myeloid sarcoma could progress to acute myeloid leukemia [3,10].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Isolated Myeloid Sarcoma Presenting as Cord Compression by Paraspinal Mass

Kim

Han

et al. 2016

Ewha Med J

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Isolated Myeloid Sarcoma Presenting as Cord Compression by Paraspinal Mass

Kim

Han

et al. 2016

Ewha Med J

View full text Add to dashboard Cite

“…The role of allo-HCT has been evaluated in several retrospective studies, most consisting of leukemic MS [29,30,31,32]. In a series of 67 MS patients, significant prolonged overall survival (OS) was achieved in 10 patients who received either allo- or auto-HCT [1].…”

Section: Discussionmentioning

confidence: 99%

Long-Term Remission following Autologous Hematopoietic Cell Transplantation in a Patient with Multiple Nonleukemic Myeloid Sarcoma and a Review of the Literature

Liang

Gao²,

Wu³

et al. 2017

Acta Haematol

View full text Add to dashboard Cite

Multiple nonleukemic myeloid sarcoma (MS) is a rare form of MS that is developed in multiple anatomic sites other than bone marrow at diagnosis, without a preceding myeloid neoplasm. The prevalence, prognosis, and optimal management of multiple nonleukemic MS have not been addressed. The role of allogenic or autologous hematopoietic cell transplantation (HCT) for nonleukemic MS is also less well defined. We present a case of MS characterized by systemic lymphadenopathies and multiple effusions, which presumably had a very poor prognosis. The patient was treated with acute myeloid leukemia-type induction chemotherapy and autologous peripheral blood stem cell transplantation, and, unexpectedly, she has remained disease free for more than 6 years. We also reviewed the literature on this rare disease, and found that multiple nonleukemic MS was associated with younger age and a worse prognosis when compared with the overall nonleukemic MS population. We suggest that autologous HCT represents a valid option for young patients with chemosensitive disease and should be performed at the status of minimal residual disease-negative complete remission.

show abstract

“…A recent study confirmed that patients treated with allogenic hematopoietic stem cell transplantation (HSCT) as post remission therapy had a longer EFS, except for a patient with high-risk cytogenetics who had poorer EFS and an increased incidence of relapse. However, the latter should be considered with caution as the cytogenetic data were missing in most cases of isolated MS [12,[14][15][16][17][18][19][20][21][22][23].…”

Section: Discussionmentioning

confidence: 99%

Progressive course of isolated splenic myeloid sarcoma

Jovanović

Knežević²,

Ostojic³

et al. 2013

Open Medicine

Self Cite

View full text Add to dashboard Cite

AbstractA previously healthy 40-year-old male presented with a 2-week history of fever and abdominal discomfort that was resistant to empirical broad-spectrum antibiotic treatment. The patient’s blood cell count and complete biochemical panel was normal, except for an increased lactate dehydrogenase level. Ultrasonography and computed tomography of the abdomen showed a large, soft tissue mass had infiltrated superior part of the spleen. Splenectomy with total tumor mass removal were performed. The pathological examination of the tumor tissue confirmed diagnosis of isolated myeloid sarcoma with monoblastic differentiation. Despite intensive antileukemic therapy, patient died four months after diagnosis was established.

show abstract

Is there a “gold” standard treatment for patients with isolated myeloid sarcoma?

Cited by 78 publications

References 16 publications

Isolated Myeloid Sarcoma Presenting as Cord Compression by Paraspinal Mass

Isolated Myeloid Sarcoma Presenting as Cord Compression by Paraspinal Mass

Long-Term Remission following Autologous Hematopoietic Cell Transplantation in a Patient with Multiple Nonleukemic Myeloid Sarcoma and a Review of the Literature

Progressive course of isolated splenic myeloid sarcoma

Contact Info

Product

Resources

About